What the FDA labels say about taking them together
Cyclosporine and everolimus
Everolimus's FDA label (Zortress) of February 12, 2026 names cyclosporine in its boxed warning section; the cyclosporine labels PlainMeds reads (4) do not name everolimus. The everolimus label: “BK virus associated nephropathy): Consider reducing immunosuppression TMA/TTP/HUS:”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the cyclosporine label say about everolimus?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name everolimus in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the everolimus label say about cyclosporine?
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), boxed warningNephrotoxicity Increased nephrotoxicity can occur with use of standard doses of cyclosporine in combination with Zortress.
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsDRUG INTERACTIONS Strong-moderate CYP3A4 inhibitors (e.g., cyclosporine, ketoconazole, erythromycin, verapamil) and CYP3A4 inducers (e.g., rifampin) may affect everolimus concentrations ( 7.1 ).
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), warnings and precautionsBK virus associated nephropathy): Consider reducing immunosuppression ( 5.13 ) TMA/TTP/HUS (concomitant use with cyclosporine may increase risk):
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Everolimus | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $26.32 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once